Allergy Diagnostic and Treatment Market By Product (Allergy Diagnostic Devices: Immunoassay Analyzer, Flow Cytometer, Lateral Flow Assay, Enzyme-linked Immunosorbent Assay (ELISA), Allergy Treatment Drugs: Antihistamines, Corticosteroids, Leukotriene Receptor Antagonists, Immunotherapy), By End-User (Hospitals and Clinics, Homecare Settings, Diagnostic Laboratories), By Distribution Channel (Direct Sales, Retail Pharmacies, Online Pharmacies); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Allergy Diagnostic and Treatment Market was valued at USD 5.9 Billion in 2024-e and will surpass USD 9.4 Billion by 2030; growing at a CAGR of 7.9% during 2025-2030.

The allergy diagnostic and treatment market is experiencing significant growth due to the increasing prevalence of allergic diseases across the globe. Allergies, ranging from seasonal pollen-induced rhinitis to more severe forms like food allergies and asthma, are becoming more widespread, particularly in urban areas with changing environmental conditions. The growing awareness about allergy management and advancements in diagnostic technologies are driving the demand for effective diagnostic devices and treatment drugs. This market includes allergy diagnostic devices for identifying allergens and allergy treatment drugs aimed at mitigating allergic reactions. The rising focus on personalized healthcare and the development of more precise treatments are also fueling market expansion.

Allergy Diagnostic Devices Segment Is Largest Due To Growing Demand for Accurate Diagnosis

Among the different products in the market, allergy diagnostic devices hold the largest share. These devices are critical for accurately identifying the specific allergens responsible for allergic reactions. Technologies such as immunoassay analyzers, flow cytometers, and lateral flow assays are widely used in clinical settings for their reliability and precision. The immunoassay analyzer is particularly prominent in this segment due to its ability to detect and quantify allergens in the blood, making it a vital tool for accurate diagnosis.

As allergies become more common globally, early and precise diagnosis is becoming essential for effective treatment planning. This is further driving the demand for allergy diagnostic devices, especially in hospitals, clinics, and diagnostic laboratories. The increasing prevalence of allergic conditions and the need for more specific tests to determine the triggers of allergies are expected to continue to boost the growth of the allergy diagnostic devices segment.

Allergy Treatment Drugs Segment Is Fastest Growing Due To Increased Demand for Effective Relief

The allergy treatment drugs segment is growing at the fastest pace, fueled by the increasing demand for effective relief from allergy symptoms. Among the treatment options, antihistamines, corticosteroids, leukotriene receptor antagonists, and immunotherapy are the most widely used. Antihistamines, particularly oral versions, continue to dominate this segment due to their rapid onset of action and ease of use. However, the fastest-growing area within the treatment drugs segment is immunotherapy. This treatment involves desensitizing the immune system to specific allergens, offering long-term relief, particularly for patients with chronic or severe allergies.

The rise in immunotherapy treatments is attributed to their ability to provide long-lasting benefits compared to conventional drugs, which often only manage symptoms temporarily. With an increasing number of patients opting for treatments that offer longer-lasting results and minimize the need for frequent medication, immunotherapy is expected to drive the fastest growth in the allergy treatment drugs segment.

Hospitals and Clinics Segment Is Largest End-User Due to Comprehensive Care

Hospitals and clinics are the largest end-user segment in the allergy diagnostic and treatment market. These healthcare settings provide comprehensive care, ranging from diagnosis to treatment and long-term management. Hospitals and clinics often offer the most advanced diagnostic technologies and a wide array of allergy treatments, including prescription drugs and immunotherapy. Furthermore, these facilities are equipped to handle severe allergic reactions and offer specialized care for patients who need tailored treatment plans.

The demand for allergy diagnostic and treatment services in hospitals and clinics is bolstered by the growing number of patients seeking professional diagnosis and management of allergic conditions. As more individuals turn to healthcare professionals for assistance in managing their allergies, hospitals and clinics remain the dominant end-user segment in the market.

Retail Pharmacies Segment Is Fastest Growing Distribution Channel Due To Convenience and Accessibility

The retail pharmacies segment is the fastest-growing distribution channel in the allergy diagnostic and treatment market. Retail pharmacies, including online pharmacies, are becoming increasingly popular due to the convenience they offer. Consumers can easily access allergy medications like antihistamines, corticosteroids, and nasal sprays over-the-counter without the need for a prescription, making this channel more appealing. Furthermore, the rise of e-commerce platforms for pharmacy products has further contributed to the segment’s rapid growth, offering consumers a wider range of allergy management options from the comfort of their homes.

As the demand for over-the-counter treatments continues to rise and the preference for accessible solutions grows, retail pharmacies are expected to remain a key player in the allergy treatment market. The shift toward online pharmacy platforms and direct-to-consumer sales channels will continue to drive the segment’s expansion, further enhancing its growth prospects.

North America Is Largest Region Due To High Incidence of Allergies and Advanced Healthcare Infrastructure

North America holds the largest share of the allergy diagnostic and treatment market, primarily driven by the high prevalence of allergies, especially in the United States. The region also benefits from advanced healthcare infrastructure, with access to state-of-the-art diagnostic devices and a broad range of allergy treatment options. As more people in North America experience allergic reactions, the demand for both diagnostic tests and treatment drugs has risen. In particular, the region sees a high consumption of over-the-counter allergy medications, as well as increasing adoption of allergy immunotherapy.

Moreover, a growing awareness of allergy-related health issues and the availability of advanced treatment options further contribute to North America’s dominant position in the market. The presence of leading pharmaceutical companies and diagnostic device manufacturers in the region also plays a crucial role in maintaining its market leadership.

Competitive Landscape: Key Players and Market Dynamics

The allergy diagnostic and treatment market is highly competitive, with numerous players offering a wide range of products to address the growing demand for allergy management. Leading companies in the market include Abbott Laboratories, Thermo Fisher Scientific, Merck & Co., GlaxoSmithKline, Sanofi, and Allergy Therapeutics. These companies are actively involved in the development of new diagnostic technologies and allergy treatments, including biologics and immunotherapy options.

The competitive landscape is characterized by continuous innovation, with a strong focus on research and development aimed at improving the efficacy, safety, and convenience of allergy treatments. Strategic partnerships, mergers, and acquisitions are common strategies among market players to strengthen their product portfolios and expand their market reach. As the market continues to grow, companies will focus on enhancing customer access to allergy care through both traditional and online distribution channels to remain competitive.

Recent Developments:

• Thermo Fisher Scientific Inc. launched a new immunoassay analyzer aimed at improving the accuracy and efficiency of allergy diagnosis.
• Abbott Laboratories introduced a portable allergy diagnostic device designed for use in both clinical and homecare settings.
• ALK-Abelló A/S received regulatory approval for a new sublingual immunotherapy treatment for grass pollen allergies.
• Merck & Co., Inc. announced the launch of a new leukotriene receptor antagonist for seasonal allergy relief.
• Siemens Healthineers AG unveiled a next-generation allergy testing platform with enhanced capabilities for diagnosing food and environmental allergens.

List of Leading Companies:

• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Abbott Laboratories
• Roche Diagnostics
• ALK-Abelló A/S
• Merck & Co., Inc.
• Danaher Corporation
• Stallergenes Greer
• Becton, Dickinson and Company
• Regeneron Pharmaceuticals, Inc.
• Novartis International AG
• GlaxoSmithKline plc
• Bayer AG
• Johnson & Johnson
• Schering-Plough Corporation

Report Scope: